Those eligible for a free influenza vaccine have to 31 July 2014 to visit their general practice and receive their immunisation.
INFLUVAC ® (Abbott, manufactured in the Netherlands); FLUARIX® (GlaxoSmithKline, manufactured in Germany) are the funded vaccines for 2014.
Vaccine Order Form - click here
Healthcare Logistics will be distributing influenza vaccines for the 2014 season. You can order influenza vaccine in two ways:
Fax: 0508 408 358
Enquiries can be made by calling 0508 425 358
Influenza vaccine damaged in transit
Influenza vaccine damaged in transit may be returned to Healthcare Logistics for destruction.
Where to return expired influenza vaccine
Expired influenza vaccine can be returned using the normal process for expired/damaged paediatric vaccine to your local ProPharma vaccine warehouse.
Refund for unused stock
It can be difficult to determine exact requirements towards the end of the influenza season. A refund will be available for a total of 10 units of unused stock of either INFLUVAC® and FLUARIX®, from any one account. Unused stock must be returned by August 31st 2014 to be refunded.
INFLUENZA VACCINE COMPOSITION for 2014
Southern Hemisphere/New Zealand/Australia
The formulation of influenza vaccines for use in New Zealand and Australia is determined each year by the Australian Influenza Vaccine Committee (AIVC) based on information and recommendations from the World Health Organization (WHO). The AVIC met on 10th October and agreed to adopt the WHO recommendations.
The influenza vaccine for the Australian 2013 influenza season contains the following three virus strains:1, 2
A/ California/7/2009 (H1N1)-like strain (15 μg HA per dose)
A/Victoria/361/2011 (H3N2)-like strain (15 μg HA per dose)
B/Wisconsin/1/2010-like strain (15 μg HA per dose)
1. World Health Organization Recommended composition of influenza virus vaccines for use in the 2014 southern hemisphere influenza season Accessed at: WHO 2014 Southern Hemisphere
2. Therapeutic Good Administration, Australian Influenza Vaccine Committee (AIVC) AIVC recommendations for the composition of influenza vaccine for 2014: TGA announcement
VACCINE FAQs (this section is yet to be updated for the 2014 season)
Do FLUVAX® and FLUARIX® contain blood products?
No blood products are used in the manufacturing process of FLUVAX® and FLUARIX®.
Do FLUVAX® and FLUARIX® contain thiomersal?
No FLUVAX® and FLUARIX® are preservative free. None of the vaccines contain thiomersal.
Do FLUVAX® and FLUARIX® contain neomycin, polymyxin or gentamicin?
Yes. FLUVAX® contains traces of neomycin and polymyxin due to the use of these substances during production. FLUARIX® contains traces of gentamicin suphate. FLUVAX® and FLUARIX® should be used with caution in subjects with a hypersensitivity to traces of these. However, these vaccines should not be used in people who have had an anaphylactic reaction to neomycin, polymyxin or gentamicin suphate.
Vaccine data sheets may vary in their recommendations or contraindications. Regarding hypersensitivity and contraindications, current best evidence for influenza vaccines and recommendations by the Immunisation Advisory Centre (IMAC) and Australian Society of Clinical Immunology and Allergy (ASCIA) are that individuals with anaphylaxis to any ingredient in the vaccine are contraindicated except egg allergy and should not receive a vaccine that includes them as residual.
Are FLUVAX® and FLUARIX® latex free?
FLUVAX® is latex free and can be used safely for those with a latex allergy. However regarding FLUARIX® some prefilled syringe models have a pre-attached needle and a typical skirted needle shield. This needle shield contains approximately 43% of dry natural rubber (DNR). These prefilled syringes with pre-attached needles are not considered latex-free.
Are there minimum order requirements?
Yes. Once the seasonal vaccine becomes available in New Zealand. The following minimum order quantities apply:
Min 50 doses
Min 50 doses
Min 30 doses
Min 30 doses
Min 20 doses
Min 10 doses